Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases

1. A compound of Formula I:

or a pharmaceutically acceptable salt or solvate thereof,

wherein

X 1 and X 5 are independently selected from the group consisting of hydrogen, halogen, C1-C4-alkyl, C1-C4-haloalkyl, cyano, nitro, di(C1-C4-alkyl)amino, —NHCOOR′, and —COOR′, wherein R′ is methyl, ethyl, n-propyl, n-butyl, iso-propyl, iso-butyl or tert-butyl;

X 2 , X 3 , X 4 are independently selected from the group consisting of hydrogen, chloro, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, cyano, nitro, di(C1-C4-alkyl)amino, —NHCOOR′, and —COOR′, wherein R′ is methyl, ethyl, n-propyl, n-butyl, iso-propyl, iso-butyl or tert-butyl; with the proviso that at least one of X 1 , X 2 , X 3 , X 4 , X 5 is not hydrogen and that at least one of X 2 , X 3 , X 4 is not C1-C4-alkoxy;

L is —NHC(O) or —NHSO 2 ;

n is 1;

m is 2, 3, 4 or 5;

R 1 is alkyl, and

R 2 is 5- or 6-membered arylalkyl, 5- or 6-membered cycloalkylalkyl, wherein the cyclic moiety of said arylalkyl or cycloalkylalkyl is optionally substituted by one or more fluoro; or

R 1 and R 2 together with the nitrogen atom to which they are attached, form a isoindolinyl group optionally substituted by one or more substituents independently selected from C1-C2 alkyl and halogen.

2. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein

n is 1 and L is —NHC(O)—.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is methyl.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is 5- or 6-membered aryl-C1-C2-alkyl.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein m is 2, 3 or 4.

6. The compound according to claim 1 , having Formula III

or a pharmaceutically acceptable salt or solvate thereof,

wherein

X 1 , X 2 , X 3 , X 4 , X 5 , L, n and m are as defined in claim 1 ;

p is 1 or 2;

X 6 , X 7 , X 8 , X 9 , X 10 are independently selected from H and fluoro.

7. The compound according to claim 1 , having Formula V

8. The compound according to claim 1 selected from the group consisting of:

N-[3-(benzylmethylamino)propyl]-4-chlorobenzensulfonamide,

4-(benzylmethylamino)-N-(4-chlorophenyl)butanamide,

N-(4-chlorobenzyl)-3-(benzylmethylamino)propanamide,

N-(4-nitrobenzyl)-3-(benzylmethylamino)propanamide,

N-(4-cyanobenzyl)-3-(benzylmethylamino)propanamide,

N-(2,4-dichlorobenzyl)-3-(benzylmethylamino)propanamide, and

N-(3-chlorobenzyl)-3-(benzylmethylamino)propanamide.

9. A pharmaceutical composition comprising an effective amount of compound according to claim 1 .